Evidence map›Paper›PMID 35117208›Full record

ArticleTranslational cancer research2020

High levels of

Lei Wang, Chunyan Yang, Fangfang Li, Dengcai Mu, Pengzhan Ran, Hao Shen, Weiyuan Li, Jiao Ma, Jianghai Wu, Xinrui Yang and 3 more

Open access · diamondAbstract read
In one paragraph

Article in Translational cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Lei Wang *School of Medicine, Yunnan University, Kunming, China.
Chunyan Yang *School of Medicine, Yunnan University, Kunming, China.
Fangfang LiSchool of Medicine, Yunnan University, Kunming, China.
Dengcai MuSchool of Medicine, Yunnan University, Kunming, China.
Pengzhan RanSchool of Medicine, Yunnan University, Kunming, China.
Hao ShenSchool of Medicine, Yunnan University, Kunming, China.
Weiyuan LiSchool of Medicine, Yunnan University, Kunming, China.
Jiao MaSchool of Medicine, Yunnan University, Kunming, China.
Jianghai Wu2nd Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Kunming Medical University, Kunming, China.
Xinrui YangSchool of Medicine, Yunnan University, Kunming, China.
Xun ShengSchool of Medicine, Yunnan University, Kunming, China.
Bei ZhuEdong Healthcare City Hospital of Traditional Chinese Medicine (Infectious Disease Hospital), Huangshi, China.
Shangyong ZhengSchool of Medicine, Yunnan University, Kunming, China.
Yunnan University · CNAnyang Hospital of Traditional Chinese Medicine · CNFirst Affiliated Hospital of Kunming Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere are growing number of researches have shown that mesoderm posterior basic helix-loop helix (BHLH) transcription factor 1 (

methods

resultsDetection of

conclusionsOur study suggested that

Indexed as

apoptosisexpressionMESP1metastasisNon-small cell lung cancer (NSCLC)

Identifiers

PMID35117208
PMCPMC8797436
OpenAlexW3086709794

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.